Autor según el artículo: Capdevila, O; Mitjavila, F; Espinosa, G; Caminal-Montero, L; Marín-Ballvè, A; León, RG; Castro, A; Canora, J; Pinilla, B; Fonseca, E; Ruiz-Irastorza, G; RELES; Autoimmune Dis Study Grp GEAS; Spanish Soc Internal Med
Departamento: Medicina i Cirurgia
Autor/es de la URV: Castro Salomó, Antoni
Palabras clave: Systemic lupus erythematosus Safety Rituximab Nephritis Erythematosus Efficacy College Cohort Belimumab
Resumen: Objectives: To analyze the characteristics and the predictive factors of the use of rituximab and belimumab in daily practice in patients from the inception cohort Registro Espanol de Lupus (RELES). Material and methods: The study included 518 patients. We considered patients treated with biologics who received at least one dose of rituximab or belimumab, and possible indications of those manifestations registered at the same time or in the previous 2 months of the start of the therapy. Results: In our cohort, 37 (7%) patients received at least one biological treatment. Rituximab was prescribed in 26 patients and belimumab in 11. Rituximab was mainly prescribed for hemolytic anemia or thrombocytopenia (11 patients, 42%), lupus nephritis and neuropsychiatric lupus (5 patients each, 19%). Belimumab was mostly used for arthritis (8 patients, 73%). In the univariate analysis, the predictive factors at diagnosis for the use of biologic therapy were younger age (p = 0.022), a higher SLEDAI (p = 0.001) and the presence of psychosis (p = 0.011), organic mental syndrome (SOCA) (p = 0.006), hemolytic anemia (p = 0.001), or thrombocytopenia (p = 0.01). In the multivariant model, only younger age, psychosis, and hemolytic anemia were independent predictors of the use of biologics. Conclusions: Rituximab is usually given to patients with hematological, neuropsychiatric and renal involvement and belimumab for arthritis. Psychosis, hemolytic anemia and age at the diagnosis of lupus were independent predictive factors of the use of biological agents. Their global effects are beneficial, with a significant reduction in SLE activity and a low rate of side effects.
Áreas temáticas: Medicine, general & internal Medicine (miscellaneous) Medicine (all) Medicina ii General medicine Educação física
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: antoni.castro@urv.cat
Identificador del autor: 0000-0001-5441-6333
Fecha de alta del registro: 2024-08-03
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.mdpi.com/1648-9144/59/8/1362
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Medicina-Lithuania. 59 (8):
Referencia de l'ítem segons les normes APA: Capdevila, O; Mitjavila, F; Espinosa, G; Caminal-Montero, L; Marín-Ballvè, A; León, RG; Castro, A; Canora, J; Pinilla, B; Fonseca, E; Ruiz-Irastorza, (2023). Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients. Medicina-Lithuania, 59(8), -. DOI: 10.3390/medicina59081362
DOI del artículo: 10.3390/medicina59081362
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2023
Tipo de publicación: Journal Publications